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CRISPR/Cas has opened the prospect of direct gene correction therapy for some
inherited retinal diseases. Previous work has demonstrated the utility of adeno-
associated virus (AAV) mediated delivery to retinal cells in vivo; however, with the
expanding repertoire of CRISPR/Cas endonucleases, it is not clear which of these
are most efficacious for retinal editing in vivo. We sought to compare CRISPR/Cas
endonuclease activity using both single and dual AAV delivery strategies for gene editing
in retinal cells. Plasmids of a dual vector system with SpCas9, SaCas9, Cas12a, CjCas9
and a sgRNA targeting YFP, as well as a single vector system with SaCas9/YFP sgRNA
were generated and validated in YFP-expressing HEK293A cell by flow cytometry and
the T7E1 assay. Paired CRISPR/Cas endonuclease and its best performing sgRNA was
then packaged into an AAV2 capsid derivative, AAV7m8, and injected intravitreally into
CMV-Cre:Rosa26-YFP mice. SpCas9 and Cas12a achieved better knockout efficiency
than SaCas9 and CjCas9. Moreover, no significant difference in YFP gene editing
was found between single and dual CRISPR/SaCas9 vector systems. With a marked
reduction of YFP-positive retinal cells, AAV7m8 delivered SpCas9 was found to have
the highest knockout efficacy among all investigated endonucleases. We demonstrate
that the AAV7m8-mediated delivery of CRISPR/SpCas9 construct achieves the most
efficient gene modification in neurosensory retinal cells in vivo.
Keywords: CRISPR (clustered regularly interspaced short palindromic repeats), retina, retinal dystrophy, gene
editing, AAV (adeno-associated virus)
INTRODUCTION
Being discovered as a critical component of some bacterial and archaea, acting to counter viral
intrusion (Jinek et al., 2012), the Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR)/CRISPR-associated protein (Cas) system has been successfully repurposed for efficient
genome editing in mammalian cells (Cong et al., 2013; Mali et al., 2013). This has opened the
door to direct gene correction therapy for many inherited retinal diseases. Nevertheless, one of
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the greatest challenges is the efficient delivery of the CRISPR/Cas
genome-editing system to the target tissues or cells in living
organisms. Due to the large size of the commonly used SpCas9
(Streptococcus pyogenes, ∼4.2 kb) and the loading capacity of
some currently available viral vectors for ocular gene therapy
such as adeno-associated virus (AAV), recent studies have
demonstrated that a dual AAV2 system can be used to deliver
CRISPR/Cas9 to effectively perform DNA editing in retinal cells
in adult mice (Bakondi et al., 2016; Hung et al., 2016; Latella et al.,
2016; Ruan et al., 2017; Yu et al., 2017; Li et al., 2019). Despite the
success of this dual-vector strategy, it is challenging to transduce
two AAVs into one cell and clearly activity of the CRISPR/Cas
machinery requires the receipt of both the endonuclease and
sgRNA expression cassettes.
With the expanding repertoire of CRISPR/Cas endonucleases,
various CRISPR/Cas systems have been developed that utilize
smaller Cas endonuclease from different bacterial species, such as
Cas12a (Acidaminococcus,∼3.9 kb or Lachnospiraceae, ∼3.7 kb),
SaCas9 (Staphylococcus aureus, 3.2 kb), CjCas9 (Campylobacter
jejuni, 2.9 kb), NmCas9 (Neisseria meningitidis,∼3.2 kb), making
it possible to use a single vector to package both the Cas
endonuclease and its sgRNA. A handful of studies have reported
the successful in vivo genome editing of SaCas9 (Maeder et al.,
2019), CjCas9 (Kim et al., 2017; Jo et al., 2019), Cas12a
(Koo et al., 2018), and NmeCas9 (Xia et al., 2018) in retinal
cells. These various CRISPR/Cas systems differ in their editing
efficacy, packageability and protospacer-adjacent motif (PAM)
requirement (listed in Supplementary Table S2), which largely
expands the in vivo application of CRISPR/Cas based genome
editing in various tissues or cells. There have been a small
number of studies, which have applied all-in-one AAV vector-
mediated CRISPR/Cas genome editing in different cells including
retinal pigment epithelium cells. Eunji and colleagues reported
the successful disruption of the Vegfa or Hif1a genes in mouse
RPE cells using single AAV-CjCas9 (Kim et al., 2017). Other
groups have utilized a single AAV vector to deliver SaCas9, or
NmeCas9 to a variety of somatic tissue in mice (Ran et al., 2015;
Ibraheim et al., 2018; Jarrett et al., 2018; Pan et al., 2018; Xu
et al., 2019). Despite the encouraging in vivo application of these
CRISPR/Cas systems, delivered via dual or all-in-one vectors, it is
not clear which are the most efficacious for retinal editing in vivo.
The aim of this study was to directly compare the CRISPR/Cas
endonuclease activity of single/dual AAV strategies for retinal
gene editing in the transgenic mice expressing a yellow
fluorescent protein (YFP) reporter. To achieve this, we designed
YFP-targeting sgRNAs for each Cas endonuclease and quantified
the editing efficiency, indicated by the disruption of YFP in vitro
and in vivo.
MATERIALS AND METHODS
Ethics Approval and Animal Maintenance
All experimental studies were performed in accordance with
the Association for Research in Vision and Ophthalmology
Statement for the Use of Animals in Ophthalmic and Vision
Research and the requirements of the National Health and
Medical Research Council of Australia (Australian Code of
Practice for the Care and Use of Animals for Scientific
Purposes). This study was approved by the Animal Ethics
Committees of the University of Tasmania (Reference Number
A0014827). CMV-Cre and Rosa26-YFP transgenic mouse lines
were maintained on a C57BL/6 background and intercrossed
to generate experimental offspring that were heterozygous for
each transgene. Adult (8–12 weeks old) CMV-Cre:Rosa26-YFP
transgenic mice (YFP mice), which express YFP throughout the
retina, were maintained and bred at the University of Tasmania
(Hobart, TAS, Australia). Animals were group housed with same-
sex littermates in Optimice micro-isolator cages (Animal Care
Systems, Centennial, CO, United States) with uninhibited access
to food and water. They were maintained on a 12 h light (50 lux
illumination) and 12 h dark (<10 lux illumination) cycle, at 20◦C
to minimize possible light-induced damage to the eye.
Design and Construction of Cas
Endonucleases and sgRNAs Vectors
Single guide RNAs targeting the same 5′ region of the YFP
gene were designed using a CRISPR design tool1 with different
relevant PAM sites (Figure 1A). Briefly, three sgRNAs for SpCas9
(referred as SpCas9-YFP sgRNA1, 2, and 3), two sgRNAs with
different lengths for Cas12a (referred as Cas12a-YFP sgRNA
20 and 23 nt), two sgRNAs for CjCas9 (referred CjCas9-
YFP sgRNA1 and 2) and one sgRNA for SaCas9 (referred
as SaCas9-YFP sgRNA, as only one possible PAM site was
found in that region) were designed. These sgRNAs were
then cloned into the AAV-U6-sgRNA-hSyn-mCherry vector
(Addgene #87916). A control sgRNA, targeting the LacZ gene (5′-
TGCGAATACGCCCACGCGAT-3′), was designed based on a
previous study by Swiech et al. (2015) and LacZ sgRNA plasmids
were generated and used for in vitro validation.
Cas endonuclease plasmids were generated following different
cloning approaches. The AAV-miniCMV-SpCas9 (SpCas9)
construct was generated by replacing the CMV promoter
with a miniCMV promoter in the AAV-CMV-SpCas9 plasmid
(Addgene #107024) via AgeI and XbaI restriction enzyme
sites. Other CRISPR/Cas endonucleases (SaCas9, Cas12a, and
CjCas9) were subcloned from AAV-CMV:NLS-SaCas9-NLS-
3xHA-bGHpA;U6: BsaI-sgRNA (kindly provided by Feng Zhang;
Addgene #61591), pcDNA3.1-hAsCpf1 (kindly provided by Feng
Zhang; Addgene #69982) and CjCas9 (kindly provided by Feng
Zhang; Addgene #68338) into AAV-CMV-SpCas9 plasmid by
replacing SpCas9.
All-in-one single vector, AAV-miniCMV-SaCas9/YFP sgRNA
or AAV-miniCMV-SaCas9/LacZ sgRNA were generated based
on the AAV-CMV:NLS-SaCas9-NLS-3xHA-bGHpA;U6: BsaI-
sgRNA (kindly provided by Feng Zhang; Addgene #61591) by
replacing the CMV promoter with miniCMV promoter, adding
SpA terminator and inserting YFP sgRNA or LacZ sgRNA.
Cell Culture and Transfection
HEK293A cells that stably express YFP (HEK293A-YFP) were
generated as previously described (Hung et al., 2016, 2018). Cells
1http://crispr.mit.edu
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FIGURE 1 | In vitro YFP sgRNA validation and selection. (A) YFP-targeting sequence for sgRNA design. YFP-targeting sgRNAs were designed (3 sgRNAs for
SpCas9, 1 sgRNA for SaCas9, 2 sgRNAs for Cas12a, and 2 for CjCas9). (B) T7E1 assay to detect cleavage efficiency for YFP. Expected cleavage products by T7E1
were detected in 2% TAE gel. * Cleavage products around 590 and 260 bp. (C) Representative fluorescence microscopy images showing YFP expression in cells
transfected with different CRISPR/Cas constructs. Scale bar: 100 µm. (D) Flow cytometry analysis for sgRNA selection. Data are represented as mean ± SEM for
4–7 independent replicates. Intergroup comparisons were performed using a one-way ANOVA and corrected for multiple comparisons. HEK293A cells without YFP
expression were also included as negative control. No significant difference in YFP editing was observed between single and dual CRISPR/SaCas9 vector systems
(p = 0.9608). Selected sgRNAs for in vivo testing were SpCas9 YFPsgRNA2, Cas12a YFP sgRNA20nt, and CjCas9 YFPsgRNA2. *p < 0.05, **p < 0.01.
were maintained in Dulbecco’s modified Eagle’s media (DMEM)
(catalog no. 11965118; Life Technologies Australia, Mulgrave,
VIC, Australia) supplemented with 10% fetal bovine serum
(Sigma-Aldrich, St. Louis, MO, United States), 2 mM glutamine
(catalog no. 2503008; Life Technologies Australia), antibiotic-
antimycotic (catalog no. 15240062; Life Technologies Australia)
in a humidified 5% CO2 atmosphere at 37◦C. HEK293A-YFP
cells were transfected with 750 ng of Cas endonuclease plasmid
(under CMV promoter) and 750 ng of related sgRNA plasmid,
or 750 ng of single SaCas9 plasmid, using lipofectamine 2000
(catalog no. 11668019; Life Technologies Australia), according
to manufacturer’s instructions. YFP expression was evaluated
10 days later by collecting images of the cell cultures using a
fluorescent microscope and by performing a flow cytometric
analysis. Genomic DNA was extracted from cells after each
treatment and used to carry out a T7 endonuclease 1 (T7E1)
assay. The detailed information of reagents is provided in
Supplementary Table S1.
For Cas endonuclease detection, HEK293A cells were
transfected with 1000 ng of the Cas endonuclease plasmid (under
the miniCMV promoter) or the CjCas9 plasmid (under CMV
promoter), and protein lysates were generated 2 days later to
perform a Western blot analysis.
Genomic DNA Extraction and T7E1
Mismatch Detection Assay
Genomic DNA was extracted with QuickExtract DNA Extraction
Solution (catalog no. QE09050; Lucigen, Biosearch technologies,
Middleton, WI, United States) and used as the DNA template
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for PCR reactions performed using KAPA HiFi HotStart
DNA Polymerase (catalog no. KR0369; Roche Diagnostics
Australia, North Ryde, NSW, Australia) with primers listed
in Supplementary Table S3 (CMV SeqFWD forward and
EYFP SURVEYOR reverse primers). PCR products were then
denatured at 95◦C for 10 min and gradually lowered to room
temperature to allow for DNA heteroduplex formation, which
were then digested by T7 Endonuclease I (catalog no. M0302S;
New England Biolabs, Ipswich, MA, United States) following
the manufacturer’s instructions. The digested products were
visualized on 2% (w/v) agarose gels.
Western Blot Analysis
To validate that Cas protein expression was being driven
effectively by the Cas endonuclease plasmids, HEK293A cells
were transfected with AAV-miniCMV-SpCas9, AAV-miniCMV-
SaCas9, AAV-miniCMV-Cas12a, AAV-miniCMV-CjCas9, and
AAV-CMV-CjCas9 (under CMV promoter) plasmids. Cells were
collected at day 2 post-transfection, and protein was extracted
as described previously (Li et al., 2019). Protein samples
were separated by using NuPAGE Electrophoresis system (Life
Technologies Australia), after which proteins were transferred
to polyvinylidene fluoride (PVDF) membranes (catalog no.
162-0177; Bio-Rad Laboratories; Hercules, CA, United States).
Membranes were blocked with 5% (w/v) skim milk in TBS-T
(10 mM Tris, 150 mM NaCl, and 0.05% Tween-20) at room
temperature for 1 h and then incubated with a mouse monoclonal
HA antibody (F-7) (1:500 dilution; catalog no. sc-7392; Santa
Cruz Biotechnology, Dallas, TX, United States) or mouse
monoclonal β-actin antibody (1:1000 dilution; catalog no. catalog
no. MAB 1501; Merck Millipore, Burlington, MA, United States)
at room temperature for 1 h. Membranes were washed, further
incubated with a horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (1:5000 dilution; catalog no. A-11045;
Life Technologies Australia) at room temperature for 1 h, and
developed using the Amersham ECL Prime Western Blotting
Detection Kit (catalog no. RPN2232; GE Healthcare Australia,
Parramatta, NSW, Australia).
Viral Production
The AAV7m8 vectors were prepared by transfecting HEK293D
cells (kindly provided by Ian Alexander, Children’s Medical
Research Institute, Australia) with the AAV-miniCMV-Cas
(SpCas9, SaCas9, Cas12a, and CjCas9), AAV-CMV-CjCas9
or AAV-CMV-mCherry, selected YFP targeting sgRNAs or
AAV-miniCMV-SaCas9/YFP sgRNA (all-in-one single vector)
plasmids, helper plasmid (pXX6; kindly provided by Richard
Samulski, The University of North Carolina School of Medicine,
United States) and AAV7m8 capsid plasmid (Addgene #64839)
using the calcium phosphate method (Hung et al., 2016). Viral
vectors were purified using an AAVpro R© Purification Kit (All
Serotypes) (catalog no. 6666; Clontech Laboratories, Mountain
View, CA, United States) 48 h after viral transduction. Viral
titrations were determined by real-time quantitative PCR using
a Fast SYBR Green Master Mix (catalog no. 4385612; Life
Technologies Australia) with AAV-ITR primers (Supplementary
Table S3). The titrations of AAV7m8 were provided in
Supplementary Table S4.
Intravitreal Injection
Mice were anesthetized with an intraperitoneal injection of
ketamine (60 mg/kg) and xylazine (10 mg/kg). Bioccular,
intravitreal injections were performed under a surgical
microscope, using a hand-pulled glass needle connected to
a 10 µL Hamilton syringe (Bio-Strategy, Broadmeadows, VIC,
Australia), as described previously (Hung et al., 2016, 2018).
Eyes with severe surgical or post-operative complications
such as ocular hemorrhage or inflammation were excluded
from the study. A scleral incision was made on the nasal
region with a 30G needle before the glass needle was inserted
into the center of vitreous cavity to inject 1 µL of the dual
vector system (2.5 × 109vg AAV7m8-Cas endonuclease
and 2.5 × 109vg AAV7m8-YFP sgRNA), the SaCas9 single
vector system (2.5 × 109vg AAV7m8-miniCMV-SaCas9/YFP
sgRNA and 2.5 × 109vg AAV7m8-mCherry) or the control
vector (2.5 × 109vg AAV7m8-mCherry). A total of 150 YFP
transgenic mice were randomly allocated to the following
groups: mCherry control (n = 11), AAV7m8-miniCMV-SpCas9
(n = 12), AAV7m8-miniCMV-SaCas9 (n = 20), AAV7m8-
miniCMV-Cas12a (n = 15), AAV7m8-CMV-CjCas9 (n = 11),
AAV7m8-miniCMV-CjCas9 (n = 9) and AAV7m8-miniCMV-
SaCas9/YFP sgRNA (n = 20), receiving the same viral injection
regimen in each eye.
Retinal Flat Mounts and Histology
Enucleated eyes were immersion fixed in ice-cold 4% (w/v)
paraformaldehyde in PBS for 1 h before the retina was removed
using a dissecting microscope as described previously (Hung
et al., 2018). Processed retinal flat mounts were stained with
NucBlueTM Live ReadyProbesTM Reagent (catalog no. R37605;
Life Technologies Australia) for 20 min at room temperature
before mounting with Dako Fluorescent mounting medium
(catalog no. s3020; DAKO, Carpinteria, CA, United States). For
histological assessment, eyes were fixed in 4% paraformaldehyde
(w/v) in PBS for 1 h and embedded in optimal cutting
temperature compound (Leica Biosystems, Germany) and
stored at −80◦C until cryosectioning. Serial 10 to 20-µm-
thick cryosections were collected directly onto FLEX glass
slides, followed by staining and mounting. Images of the
retina were collected using an Olympus VS120 Slide Scanner
or Perkin Elmer Spinning Disk Confocal Microscope (Zeiss
spinning disk, Germany).
Retinal Dissociation and Flow Cytometry
Analysis
Retinas were rapidly dissected and digested using a papain
dissociation kit (catalog no. LK003176; Worthington
Biochemical Corporation, Lakewood, NJ, United States)
following the manufacturer’s instructions to obtain a
homogenous cell suspension. After dissociation, retinal cells
were resuspended in FACS buffer (1% Bovine Serum Albumin
in Phosphate Buffered Saline) and stained with DAPI (5 µg/mL;
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catalog no. D1306; Life Technologies Australia) to exclude dead
cells. Dissociated retinal cells from C57BL/6 mice were used as
a negative control for YFP expression. Live retinal cells with
mCherry (532 nm, 622/22 nm) and/or YFP (488 nm, 513/26 nm)
expression were detected by flow cytometry (MoFlo ASTRIOS;
Beckman Coulter, Brea, CA, United States). We quantified the
proportion of mCherry-labeled cells that co-labeled for YFP in
each retina using FlowJo analysis software (FlowJo R©; FlowJo
LLC, Ashland, OR, United States). Eyes with severe surgical
complications such as cataract or retinal detachment or those
with negligible mCherry expression were excluded from the
final FACS analysis.
Statistical Analysis
GraphPad Prism7 software (GraphPad Software, Inc., La Jolla,
CA, United States) was used for statistical analyses. The
D’Agostino-Pearson test for normality was performed. Data are
represented as mean ± SEM, and were analyzed using unpaired
one-way analyses of variance (ANOVA). A value of p < 0.05 was
considered statistically significant.
RESULTS
In vitro YFP sgRNA Selection and Cas
Endonuclease Validation
To select the most effective sgRNA for each Cas endonuclease,
we first validated the on-target editing efficacy of different Cas
endonucleases together with their respective sgRNAs using a
T7E1 assay in HEK293A-YFP cells. Robust cleavage activity was
evident in the groups transfected with the Cas endonuclease and
their respective YFP-targeting sgRNAs, except for those treated
with either CjCas9-YFP targeting constructs or LacZ-targeting
controls (Figure 1B). Here, SpCas9-YFP targeting constructs
were the most efficacious at knocking out YFP transgene
expression, followed by Cas12a-YFP and SaCas9-YFP targeting
constructs (Figure 1C).
The YFP disruption efficacy for each CRISPR/Cas construct
was further quantified through flow cytometric analysis
(Figure 1D). Compared to LacZ sgRNA counterparts, the
percentage of YFP-expressing cells was significantly reduced
by those transfected with SpCas9 and a YFP-targeting sgRNA
(YFP sgRNA1: 26.0 ± 2.9%, n = 7, p < 0.0001; YFP sgRNA2:
11.5 ± 1.3%, n = 7, p < 0.0001; and YFP sgRNA3: 14.7 ± 2.9%,
n = 7, p < 0.0001). Similarly, Cas12a-targeting conditions
resulted in appreciable YFP transgene knockout with a preference
for a 20 nt-protospacer (YFP sgRNA 20 nt: 33.6 ± 4.9%, n = 7,
p < 0.0001; and 23 nt sgRNA: 55.0 ± 5.0%, n = 7, p < 0.0001).
Comparatively, CjCas9 was less effective at abrogating YFP
transgene expression (YFP sgRNA2: 69.5 ± 3.1%, n = 7,
p = 0.0011) and failed to induce significant gene knockout in
one of the conditions (CjCas9-YFP sgRNA1: 83.7 ± 0.7%, n = 7,
p = 0.999); while there was no significant difference in editing
efficiency (p = 0.9608) between the use of the SaCas9 single
CRISPR construct (SaCas9/YFP-targeting sgRNA: 57.3 ± 3.2%,
n = 4) and the dual CRISPR/Cas construct system (SaCas9 and
its YFP-targeting sgRNA: 57.0 ± 2.0%, n = 7). The most effective
YFP-targeting sgRNA for each Cas endonuclease (YFP sgRNA2
for SpCas9, 20 nt YFP sgRNA for Cas12a and YFP sgRNA2 for
CjCas9) were selected for subsequent in vivo testing.
To validate the protein expression of HA-tagged Cas
endonuclease in a recombinant AAV vector (driven by
minimal promoter, miniCMV or full-length CMV promoter),
HEK293A cells were transfected with AAV-miniCMV-SpCas9,
AAV-miniCMV-SaCas9, AAV-miniCMV-Cas12a, AAV-
miniCMV-CjCas9, and AAV-CMV-CjCas9. Cas endonuclease
protein expression was evident with the use of the minimal
promoter, except for AAV-miniCMV-CjCas9 (Supplementary
Figure S1), which required the full-length CMV promoter to
drive transgene expression. Therefore, four AAV-miniCMV-
Cas endonucleases (SpCas9, SaCas9, and Cas12a) and the
AAV-CMV-CjCas9 plasmid were used along with their selected
sgRNAs for further in vivo CRISPR/Cas editing comparison.
In vivo AAV7m8 Delivery of CRISPR/Cas
in the Mouse Retina
AAV7m8-mediated gene expression (mCherry) and distribution
were assessed on retinal sectioning/flatmounts of the CMV-
Cre:Rosa26-YFP mouse eye 5 months after intravitreal injection
(Figure 2A). Retinal flatmount images from AAV7m8-
CRISPR/Cas-injected retina showed robust expression of
mCherry, although there was variation in fluorescence intensity
across quadrants (Figure 2B). Fluorescence images revealed
AAV7m8 transduction (as indicated by mCherry expression) was
visible throughout the retina, including the ganglion cell layer
(GCL), inner nuclear layer (INL) and even some parts of the
retinal outer nuclear layer (ONL), with major expression within
INL (Figure 2C and Supplementary Figure S3). Moreover, YFP
expression could be found in all the layers of the retina with no
observable difference between AAV7m8-CRISPR/Cas-treated
mice and control mice.
Comparison of YFP Knockout in the
Mouse Retina With Different Cas
Endonucleases Constructs
Five dual AAV7m8-CRISPR/Cas constructs (miniCMV-SpCas9,
miniCMV-SaCas9, miniCMV-Cas12a, miniCMV-CjCas9,
and CMV-CjCas9) with their selected YFP-targeting sgRNA
and a single all-in-one AAV7m8-SaCas9 CRISPR construct
(miniCMV-SaCas9/YFP-targeting sgRNA) were used to compare
the editing efficacy in the retinal cell in vivo (Figure 3A). To
evaluate and compare the YFP knockout in vivo delivered by
AAV7m8-mediated different CRISPR/Cas system, the percentage
of YFP disruption among mCherry positive retinal cells was
quantified by flow cytometry (Figure 3B). The flow cytometric
gating strategy is shown in Supplementary data (Supplementary
Figure S2). Representative dot plots in Figure 3B illustrate the
difference in YFP disruption in retinal cells receiving AAV7m8-
SpCas9 CRISPR vector or control vector. Differences in AAV7m8
transduction efficiency were observed between CRISPR/Cas
treatment groups (Figure 3C) with a lower percentage of
mCherry positive cells observed in the retinas transfected with
AAV7m8-Cas12a (35.1 ± 2.8%, n = 15) and AAV7m8-CjCas9
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FIGURE 2 | AAV7m8 mediated delivery of CRISPR/Cas to the mouse retina in vivo. (A) Schematic diagram of in vivo experiment. Mice were sacrificed 5 months
after intravitreal injection. (B) Representative cross section image from retina co-transduced with AAV7m8-CRISPR/Cas and its selected YFP sgRNA. Mouse ID 29,
right eye Robust AAV7m8 transductions in the retina were found. Scale bar: 200 µm. Images were taken by a Zeiss spinning disk confocal microscope. (C)
Representative retinal whole-mount images from a mouse eye receiving AAV7m8-CRISPR/Cas and its selected YFP sgRNA. Mouse ID 76, right eye. Scale bar: 500
µm. Images were taken using an Olympus Slide Scanner. Please see Supplementary Figure S3 for representative cross-sectional images with higher magnification.
(28.6 ± 3.4%, n = 9) vectors. Retinas receiving AAV7m8-SpCas9
and AAV7m8-SaCas9 (both single and dual vector system)
vectors had a relatively high proportion of mCherry expression
(50.0 ± 4.6%, n = 12; 52.0 ± 4.3%, n = 20; 57.7 ± 3.3%, n = 19
respectively). For YFP disruption, AAV7m8-SpCas9 vector
(18.9 ± 2.9%, n = 12) had the highest knockout efficiency of
YFP among all the CRISPR/Cas systems, followed by AAV7m8-
SaCas9 (single vector system: 8.4 ± 3.4%, n = 20; dual vector
system: 9.8 ± 2.6%, n = 20) and Cas12a (5.4 ± 2.0%, n = 15),
while AAV7m8-CjCas9 showed no disruption of YFP expression
(Figure 3D). Moreover, there was no significant difference in
the YFP disruption in the retinas receiving single and dual
AAV7m8-SaCas9 vectors (single vector system: 8.4 ± 3.4% vs.
dual vector system: 9.8 ± 2.6%, n = 20, p = 0.9994) (Figure 3D).
Despite efficiency in vivo YFP knockout in animals administered
AAV7m8-SpCas9, AAV7m8-SaCas9 and AAV7m8-Cas12a
vectors, there was a high degree of variability between individual
animals within identical treatment groups.
DISCUSSION
In this study, we provide a direct comparison of the efficacy
for retinal editing in vivo with four different currently available
CRISPR/Cas systems. Here, we showed that SpCas9 and Cas12a
achieved better knockout efficiency than SaCas9 and CjCas9
in vitro. AAV7m8-packaged CRISPR/Cas construct with SpCas9
was found to have the highest editing efficacy among all Cas
endonucleases in vivo. No significant difference in YFP gene
editing was found between single and dual CRISPR/SaCas9
vector systems in vitro and in vivo.
This study was based on our previous work, which used
AAV2-mediated delivery of CRISPR/Cas9 to achieve efficient
gene editing in the inner layer of retina in Thy1-YFP mice
(Hung et al., 2016). To assess and compare the genome
efficiency in the whole retina, we applied a different murine
model CMV-Cre:Rosa26-YFP transgenic mice (YFP mouse)
which express YFP throughout the retina. To this end,
we used the AAV7m8-pseudotype, an AAV2-based variant
with enhanced retinal transduction when delivered through
intravitreal injection (Dalkara et al., 2013; Khabou et al.,
2016). As the degeneration of RPE and photoreceptors are
involved in the majority of inherited retinal diseases, efficient
gene delivery of CRISPR constructs to the outer layer of
retina is imperative for therapeutic retinal gene editing.
Subretinal injection of conventional AAVs (e.g., AAV2) has
high photoreceptor transduction rate, but it is surgically
challenging with more complications. In addition, the cellular
transduction is confined within the injection bubble of the
retina. mCherry expression was generally observed in at
least two quadrants on retinal flat mount (Figure 2B), and
any variation in distribution of transfection is likely to be
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FIGURE 3 | Comparison of YFP disruption in retinal cells with different CRISPR/Cas systems delivered by AAV7m8. (A) Schematic of the dual and single vector
systems. For dual vector plasmids, the Cas endonuclease was driven by miniCMV or CMV promoter, whilst the sgRNA was driven by U6 promoter and mCherry
under the control of CMV promoter to confirm vector transfection. For the single vector systems, an all-in-one plasmid with SaCas9 was designed with the Cas
endonuclease being driven by a miniCMV promoter and sgRNA by U6 promoter. For Cas12a, we used the Cas endonuclease from Acidaminococcus (originally
designated AsCpf1). A hemagglutinin (HA) tag was fused to the C-terminus of Cas endonuclease in the vector. (B) Representative FACS plots of dissociated retinal
cells receiving different AAV7m8-CRISPR/Cas/AAV7m8-YFP sgRNA. The histograms in the lower panels (lower panel) were based on mCherry gating. Dissociated
cells from one retina were used in each group. (C) Comparison of AAV7m8 transduction in the retina indicated by mCherry expression by FACS. Data are presented
as mean ± SEM for 9–20 independent samples in each group. The D’Agostino-Pearson normality test was performed, and all groups were found to have a
Gaussian distribution. Statistical analysis between groups was performed using one-way ANOVA followed by multiple comparisons test. (D) Comparison of YFP
disruption in mCherry positive cells by FACS. Data are presented as mean ± SEM for 9–20 independent samples in each group. Data in two groups (Cas12a and
Dual SaCas9) were found to not pass the D’Agostino-Pearson normality test, and as such the Kruskal–Wallis test was used. *p < 0.05, **p < 0.01, ***p < 0.001.
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due to stochastic or technical issues. Nonetheless, our study
shows that AAV7m8-mediated CRISPR/Cas has reasonable
pan-retinal transduction.
The stringent design of this study ensured a fair comparison
of editing efficiency between different CRISPR/Cas systems. First,
we analyzed the YFP coding sequence for all potential PAM sites
for each Cas endonuclease and then designed sgRNA targeting
YFP within a similar region. Previous work has shown that both
guide RNA sequence and target gene-chromatin accessibility
can directly influence CRISPR/Cas editing efficiencies. An
important limitation of this work is the fact that we could not
directly compare identical sequences across all endonucleases.
Although we sought to target the same region within YFP,
given their differing PAM requirements, each endonuclease had a
different guide sequence, which may have directly biased editing
efficiencies. Further, these PAM restrictions also limited the
number of guide RNAs which could be directly tested. Naturally,
there is a tradeoff between targeting the same genic region and
ensuring similar ‘a priori’ guide RNA efficacy, and it is important
to note that both factors should be considered in direct head-to-
head comparisons. To further mitigate biases, we employed the
same ubiquitous promoter (CMV for in vitro sgRNA selection,
miniCMV for in vivo) for each endonuclease, and employed for
the same virus. The only exception to this design was the use of
the more potent CMV promoter for in vivo CjCas9 constructs,
due to its poor expression on western blots of in vitro HEK293A
cells. Despite this modification, CjCas9 barely demonstrated YFP
knockout on flow cytometric analysis of in vivo specimens. We
hypothesize that variation in CjCas9 codon-optimization may
account for the differences observed in study compared to that
reported by other groups (Kim et al., 2017).
We additionally found differences in gene knockout efficiency
between in vitro and in vivo modes. For the in vitro study,
SpCas9 outperformed Cas12a, followed by SaCas9 and CjCas9.
For in vivo samples, SpCas9 remained the best-performing Cas
endonuclease among all, without a clear trend among the other
Cas orthologs. Initially, we hypothesized that the single all-in-
one SaCas9 vector expressing both the SaCas endonuclease and
its respective sgRNA may have a competitive or even higher
editing efficiency compared to dual-vector mediated-editing with
SpCas9, but we did not observe this result in our in vivo test.
In this proof-of-concept study, we engineered CMV-
Cre:Rosa26-YFP mice. The principal advantage of screening a
reporter gene at the Rosa26 locus, is that genomic edits could
be readily quantified (using flow cytometry), at a single site.
That is, only a single integration event would have occurred
for our chosen reporter. Nevertheless, there are important
limitations of this model, and it must be noted that Rosa26 locus
is naturally permissive for DNA targeting. As such, our results
may not be directly transferrable or representative for other
endogenous genes, and likely represent the upper bounds for
editing efficiencies.
In summary, we demonstrate that AAV7m8-mediated delivery
of a SpCas9 construct appeard to achieve the most efficient
gene modification in retinal cells in vivo among four currently
available CRISPR/Cas systems. Ongoing research investigating
different guide sequences at different loci is required before
firm conclusions regarding retinal cell gene editing of different
endonucleases can be made.
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